U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06934200) titled 'Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels' on April 11.
Brief Summary: In this project, the investigators would like to learn if 24 weeks (about 5 and a half months) of omalizumab injections, given every 2 weeks, will be safe and effective for food allergic people who have a total immunoglobulin E (IgE) above the current FDA approved dosing regimen enabling a person to increase tolerance to the food(s) that the person is allergic to.
The investigators would also like to learn if participants who demonstrate increased tolerance to food after 24 weeks of omalizumab, can introduce the foo...